SE
MCID: STT001
MIFTS: 60

Status Epilepticus (SE)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Status Epilepticus

MalaCards integrated aliases for Status Epilepticus:

Name: Status Epilepticus 12 53 29 55 6 44 15 73
Generalized Convulsive Status Epilepticus 53
Grand Mal Status Epilepticus 73
Grand Mal Status 12
Gcse 53
Se 53

Classifications:



External Ids:

Disease Ontology 12 DOID:1824
MeSH 44 D013226
NCIt 50 C85079
SNOMED-CT 68 13973009
ICD10 33 G41

Summaries for Status Epilepticus

MalaCards based summary : Status Epilepticus, also known as generalized convulsive status epilepticus, is related to febrile infection-related epilepsy syndrome and epilepsy, and has symptoms including seizures and symptomatic seizures. An important gene associated with Status Epilepticus is GALC (Galactosylceramidase), and among its related pathways/superpathways are Circadian entrainment and MAPK signaling pathway. The drugs Valproic Acid and Piracetam have been mentioned in the context of this disorder. Affiliated tissues include brain, temporal lobe and liver, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 76 Status epilepticus (SE) is a single epileptic seizure lasting more than five minutes or two or more... more...

Related Diseases for Status Epilepticus

Diseases related to Status Epilepticus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 324)
# Related Disease Score Top Affiliating Genes
1 febrile infection-related epilepsy syndrome 33.9 POLG SCN1A
2 epilepsy 30.5 BDNF GAL GRIN2B LGI1 POLG SCN1A
3 brain injury 30.4 BDNF CASP3 ENO2 GFAP
4 limbic encephalitis 30.2 GRIA1 GRIN2B LGI1
5 temporal lobe epilepsy 30.1 BDNF CALB1 GFAP LGI1 NPY NTRK2
6 depression 30.1 BDNF GRIA1 GRIA2
7 traumatic brain injury 30.0 BDNF CASP3 ENO2 GFAP
8 neonatal hypoxic and ischemic brain injury 29.8 BDNF ENO2 PVALB
9 west syndrome 29.4 GRIN2B NTRK2 PVALB SCN1A
10 autism 29.2 BDNF GABRA4 GRIN2B PVALB SCN1A
11 bipolar disorder 29.2 BDNF GRIA1 GRIN2B NTRK2 POLG PVALB
12 attention deficit-hyperactivity disorder 29.2 BDNF FOS GRIN2B NPY NTRK2
13 schizophrenia 28.9 BDNF CALB1 GAP43 GRIA1 GRIA2 GRIN2B
14 new-onset refractory status epilepticus 12.9
15 epileptic encephalopathy, early infantile, 6 11.8
16 epilepsy, pyridoxine-dependent 11.7
17 ring chromosome 20 11.5
18 benign childhood occipital epilepsy, panayiotopoulos type 11.5
19 mitochondrial dna depletion syndrome 4a 11.5
20 ceroid lipofuscinosis, neuronal, 10 11.4
21 benign familial neonatal epilepsy 11.4
22 salt and pepper developmental regression syndrome 11.2
23 spinocerebellar ataxia 27 11.2
24 epileptic encephalopathy, early infantile, 25 11.2
25 eastern equine encephalitis 11.2
26 chd2 myoclonic encephalopathy 11.2
27 continuous spike-wave during slow sleep syndrome 11.2
28 encephalopathy 10.6
29 encephalitis 10.6
30 seizure disorder 10.3
31 ocular motor apraxia 10.3
32 creutzfeldt-jakob disease 10.3
33 neurosyphilis 10.3
34 breast fibrosarcoma 10.2 CALB1 PVALB
35 intracranial cysts 10.2 ENO2 GFAP
36 cardiac arrest 10.2
37 primitive neuroectodermal tumor of the cervix uteri 10.2 ENO2 GFAP
38 melanotic medulloblastoma 10.2 ENO2 GFAP
39 epilepsy, idiopathic generalized 10 10.2
40 cat-scratch disease 10.2
41 early myoclonic encephalopathy 10.2
42 adjustment disorder 10.1 GAL NPY
43 ganglioneuroma 10.1 ENO2 GFAP NTRK2
44 cerebellar medulloblastoma 10.1 ENO2 GFAP
45 spinal cord injury 10.1 BDNF CASP3 GFAP
46 nervous system cancer 10.1 CASP3 ENO2 GFAP
47 nodular ganglioneuroblastoma 10.1 BDNF ENO2 NTRK2
48 aphasia 10.1
49 focal epilepsy 10.1
50 pulmonary large cell neuroendocrine carcinoma 10.1 ENO2 NTRK2

Comorbidity relations with Status Epilepticus via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Alzheimer Disease
Bronchitis Cerebral Atherosclerosis
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Status Epilepticus:



Diseases related to Status Epilepticus

Symptoms & Phenotypes for Status Epilepticus

UMLS symptoms related to Status Epilepticus:


seizures, symptomatic seizures

MGI Mouse Phenotypes related to Status Epilepticus:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 BDNF CALB1 CASP3 ENO2 FOS GABRA4
2 growth/size/body region MP:0005378 10.39 BDNF CASP3 ENO2 FOS GAL GALC
3 cellular MP:0005384 10.29 BDNF CASP3 ENO2 FOS GAL GALC
4 nervous system MP:0003631 10.26 BDNF CALB1 CASP3 ENO2 FOS GABRA4
5 homeostasis/metabolism MP:0005376 10.22 BDNF CASP3 FOS GAL GALC GFAP
6 mortality/aging MP:0010768 10.17 BDNF CASP3 FOS GALC GAP43 GFAP
7 integument MP:0010771 10.07 BDNF CASP3 FOS GABRA4 GAL GRIA1
8 hearing/vestibular/ear MP:0005377 9.98 BDNF CALB1 CASP3 FOS GRIA2 NTRK2
9 no phenotypic analysis MP:0003012 9.81 BDNF CASP3 GABRA4 GRIA1 GRIA2 GRIN2B
10 normal MP:0002873 9.73 BDNF CALB1 FOS GABRA4 GFAP GRIA1
11 vision/eye MP:0005391 9.32 BDNF CASP3 FOS GALC GAP43 GFAP

Drugs & Therapeutics for Status Epilepticus

Drugs for Status Epilepticus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valproic Acid Approved, Investigational Phase 3,Phase 2,Not Applicable 99-66-1 3121
2 Piracetam Approved, Investigational Phase 3,Phase 2 7491-74-9
3
Phenytoin Approved, Vet_approved Phase 3 57-41-0 1775
4
Lorazepam Approved Phase 3,Phase 2,Phase 1,Not Applicable 846-49-1 3958
5
Midazolam Approved, Illicit Phase 3,Not Applicable 59467-70-8 4192
6
Phenobarbital Approved, Investigational Phase 3,Phase 2 50-06-6 4763
7
Sage Approved Phase 3,Phase 1,Phase 2
8
Clonazepam Approved, Illicit Phase 3 1622-61-3 2802
9
Fosphenytoin Approved, Investigational Phase 3 93390-81-9 56339
10
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 439-14-5 3016
11
Paraldehyde Approved, Investigational Phase 3 123-63-7 31264
12
Topiramate Approved Phase 3 97240-79-4 5284627
13
Eslicarbazepine acetate Approved Phase 3 75970-99-9, 236395-14-5 123618
14
Ezogabine Approved, Investigational Phase 3 150812-12-7 121892
15
Lacosamide Approved Phase 3 175481-36-4, 860352-01-8 219078
16
Pregabalin Approved, Illicit, Investigational Phase 3,Phase 2 148553-50-8 5486971
17
Clobazam Approved, Illicit Phase 3 22316-47-8 2789
18
Thiopental Approved, Vet_approved Phase 3,Not Applicable 76-75-5 3000715
19
Ketamine Approved, Vet_approved Phase 3,Phase 2 6740-88-1 3821
20
Propofol Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 2078-54-8 4943
21
gamma-Aminobutyric acid Approved, Investigational Phase 2, Phase 3 56-12-2 119
22
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
23
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 46835353 6436030 5284616
24
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177
25
Ethanol Approved Phase 3 64-17-5 702
26 Strawberry Approved Phase 3
27
Acetazolamide Approved, Vet_approved Phase 2, Phase 3 59-66-5 1986
28
Pentobarbital Approved, Investigational, Vet_approved Phase 3 76-74-4 4737
29
Glutamic Acid Approved, Nutraceutical Phase 2, Phase 3 56-86-0 33032
30 Etiracetam Investigational Phase 3,Phase 2,Not Applicable 33996-58-6
31 Anticonvulsants Phase 3,Phase 2,Phase 1,Not Applicable
32 Psychotropic Drugs Phase 3,Phase 2,Phase 1,Not Applicable
33 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
35 GABA Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Tranquilizing Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Antimanic Agents Phase 3,Phase 2,Not Applicable
38 Nootropic Agents Phase 3,Phase 2,Not Applicable
39 Protective Agents Phase 3,Phase 2
40 Neuroprotective Agents Phase 3,Phase 2
41 Diuretics, Potassium Sparing Phase 3
42 Sodium Channel Blockers Phase 3
43 Anti-Anxiety Agents Phase 3,Phase 2,Phase 1,Not Applicable
44 GABA Modulators Phase 3,Phase 2,Phase 1,Not Applicable
45 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
48 Hypnotics and Sedatives Phase 3,Phase 2,Phase 1,Not Applicable
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
50 Anesthetics, Intravenous Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy Unknown status NCT01645072 Phase 3
2 Refractory Status Epilepticus Treatment Study Completed NCT01586208 Phase 3 valproic acid (VPA)
3 Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan Completed NCT02239380 Phase 3 Lorazepam
4 Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting Completed NCT03650270 Phase 3 Phenobarbital
5 Evaluation of Therapeutic Hypothermia in Convulsive Status EPILEPTICUS in Adults in Intensive Care Completed NCT01359332 Phase 3
6 A Study With SAGE-547 for Super-Refractory Status Epilepticus Completed NCT02477618 Phase 3 SAGE-547;Placebo
7 Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus Completed NCT01870024 Phase 3 Clonazepam;Fosphenytoin;Placebo;Lorazepam
8 Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus Completed NCT01150331 Phase 3 Levetiracetam/Clonazepam;Clonazepam/Placebo levetiracetam IV
9 Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus Completed NCT00004297 Phase 3 diazepam;lorazepam
10 Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications Completed NCT00809146 Phase 3 Intramuscular route of active treatment;Intravenous route of active treatment
11 Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2) Completed NCT00621478 Phase 2, Phase 3 lorazepam or diazepam
12 Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children Completed NCT00735527 Phase 3 Lorazepam;Lorazepam
13 Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions Completed NCT00116064 Phase 3 intranasal lorazepam;intramuscular paraldehyde
14 An Open-Label Extension Study to Evaluate the Safety and Tolerability of RWJ 333369 as Adjunctive Therapy in Patients 16 Years and Older With Partial Onset Seizures. Completed NCT00991757 Phase 3 carisbamate
15 The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin Completed NCT00908453 Phase 3 fosphenytoin
16 A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure Completed NCT00230698 Phase 3 topiramate
17 Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Completed NCT00866775 Phase 3 Eslicarbazepine acetate;Eslicarbazepine acetate
18 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic Completed NCT01091662 Phase 3 Eslicarbazepine acetate 1600 mg;Eslicarbazepine acetate 1200 mg
19 Modified Atkins Diet in Childhood Epilepsy Completed NCT00836836 Phase 2, Phase 3
20 Conversion to Monotherapy Study With Keppra XR for Partial Seizures Completed NCT00419094 Phase 3 Keppra XR;Keppra XR
21 Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures Completed NCT01227902 Phase 3 Retigabine IR
22 Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures Completed NCT00520741 Phase 3 Lacosamide;Lacosamide
23 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy Completed NCT00101933 Phase 3
24 Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS) Completed NCT01336621 Phase 3 Retigabine IR
25 Established Status Epilepticus Treatment Trial Recruiting NCT01960075 Phase 3 Fosphenytoin;Levetiracetam;Valproic acid
26 Ketamine in Refractory Convulsive Status Epilepticus Recruiting NCT02431663 Phase 3 Ketamine
27 Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan Recruiting NCT03336645 Phase 3 SHP615
28 Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus Recruiting NCT03115489 Phase 2, Phase 3 Traditional Treatment (Group T);Ketamine Infusion (Group K)
29 Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting Recruiting NCT03336450 Phase 3 SHP615;MHOS/SHP615
30 Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome Recruiting NCT03047980 Phase 2, Phase 3 Sirolimus
31 A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome Active, not recruiting NCT02682927 Phase 3 ZX008 (Fenfluramine Hydrochloride);Matching Placebo
32 A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Active, not recruiting NCT02544763 Phase 3 GWP42003-P;Placebo
33 Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome Enrolling by invitation NCT02904265 Phase 2, Phase 3 Diazepam;Acetazolamide
34 An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Enrolling by invitation NCT02544750 Phase 3 GWP42003-P
35 Treatment of Refractory Status Epilepticus Terminated NCT00265616 Phase 3 propofol;thiopental/pentobarbital
36 Randomized Trial Comparing 3 Routes of Delivering Lorazepam to Children. Terminated NCT00343096 Phase 3 Lorazepam
37 Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures Terminated NCT01648101 Phase 3 Retigabine 900mg/day;Retigabine 600mg/day
38 Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures Terminated NCT00524030 Phase 3 pregabalin 600 mg/day;pregabalin 150 mg/day
39 Clobazam Use in Epilepsia Partialis Continua - Pilot Study Terminated NCT02134366 Phase 3 Clobazam;Clonazepam;Lorazepam
40 Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus Withdrawn NCT02726867 Phase 3 levetiracetam;lacosamide;Ketamine;Phenobarbital
41 Safety and Tolerability Study of Levetiracetam to Treat Patients With Status Epilepticus Unknown status NCT00362141 Phase 2 levetiracetam (add-on)
42 Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus Completed NCT02052739 Phase 1, Phase 2 SAGE-547
43 Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus Completed NCT02920060 Phase 2 Intravenous levetiracetam;Sodium valproate
44 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
45 Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus Recruiting NCT03025906 Phase 2 Phenobarbital;Valproate
46 Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus Recruiting NCT03350035 Phase 2 Ganaxolone;Placebo
47 Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome Active, not recruiting NCT02332655 Phase 1, Phase 2 Cannabidiol
48 Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus Withdrawn NCT00603135 Phase 2 first-line i/v-levetiracetam
49 Lorazepam for the Treatment of Status Epilepticus in Children Completed NCT00114569 Phase 1 lorazepam
50 Safety and Efficacy of Intravenous Valproate in Pediatric Status Epilepticus and Acute Repetitive Seizures Unknown status NCT01268904 Valproate

Search NIH Clinical Center for Status Epilepticus

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: status epilepticus

Genetic Tests for Status Epilepticus

Genetic tests related to Status Epilepticus:

# Genetic test Affiliating Genes
1 Status Epilepticus 29

Anatomical Context for Status Epilepticus

MalaCards organs/tissues related to Status Epilepticus:

41
Brain, Temporal Lobe, Liver, Cortex, Amygdala, Heart, Kidney

Publications for Status Epilepticus

Articles related to Status Epilepticus:

(show top 50) (show all 1839)
# Title Authors Year
1
Degeneration of cholinergic basal forebrain nuclei after focally evoked status epilepticus. ( 30243733 )
2019
2
Sodium valproate suppresses abnormal neurogenesis induced by convulsive status epilepticus. ( 30539816 )
2019
3
Recurrent Metabolic Acidosis during High-dose Midazolam Therapy for Refractory Status Epilepticus. ( 29531455 )
2018
4
A Comparative Study of Midazolam and Target-Controlled Propofol Infusion in the Treatment of Refractory Status Epilepticus. ( 29962746 )
2018
5
Expanding the phenotype of TRAK1 mutations: hyperekplexia and refractory status epilepticus. ( 29846532 )
2018
6
Hyperammonemia Presenting as Refractory Status Epilepticus after Lung Transplant in a Patient Positive for <i>Ureaplasma parvum</i>. ( 29962751 )
2018
7
Genetic etiologies of the electrical status epilepticus during slow wave sleep: systematic review. ( 29976148 )
2018
8
Pediatric refractory and super-refractory status epilepticus. ( 29941225 )
2018
9
The differential roles of PEA15 phosphorylations in reactive astrogliosis and astroglial apoptosis following status epilepticus. ( 29438777 )
2018
10
New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): State of the art and perspectives. ( 29476535 )
2018
11
Status Epilepticus: Behavioral and Electroencephalography Seizure Correlates in Kainate Experimental Models. ( 29410648 )
2018
12
Convulsive status epilepticus management in adults and children: Report of the Working Group of the Polish Society of Epileptology. ( 29937151 )
2018
13
Loss of Vestibular Ocular Reflex in Nonconvulsive Status Epilepticus. ( 29951957 )
2018
14
Successful Phenobarbital Desensitization After DRESS Reaction in the Management of Refractory Status Epilepticus. ( 29390946 )
2018
15
Recurrent hepatic failure and status epilepticus: an uncommon presentation of hyperargininemia. ( 29961243 )
2018
16
Hypothermia Reduces Mortality, Prevents the Calcium Plateau, and Is Neuroprotective Following Status Epilepticus in Rats. ( 29942282 )
2018
17
The effect of vagus nerve stimulator in controlling status epilepticus in children. ( 29414137 )
2018
18
Status epilepticus due to acute encephalitis: NORSE does not necessarily mean worse. ( 29938873 )
2018
19
Systemic Complications Following Status Epilepticus. ( 29417304 )
2018
20
Evaluation of STESS, mRSTESS, and EMSE to Predict High Disability and Mortality at Hospital Discharge in Ecuadorian Patients with Status Epilepticus. ( 29949007 )
2018
21
Successful Use of Ketamine for Burst Suppression in Super Refractory Status Epilepticus Following Substance Abuse. ( 29422735 )
2018
22
Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: A systematic review. ( 29428899 )
2018
23
The Synergistic Effect of Raloxifene, Fluoxetine, and Bromocriptine Protects Against Pilocarpine-Induced Status Epilepticus and Temporal Lobe Epilepsy. ( 29881945 )
2018
24
Case Report: Fulminant Murine Typhus Presenting with Status Epilepticus and Multi-Organ Failure; an Autopsy Case and a Review of the Neurologic Presentations of Murine Typhus. ( 29943716 )
2018
25
Cerebral Venous Sinus Thrombosis with Cerebral Hemorrhage Presenting with Status Epilepticus in Early Pregnancy. ( 29739085 )
2018
26
Treat the Patient, Not the Test When a Hospitalized Patient in Status Epilepticus Transitions to Comfort-Focused Goals of Care. ( 29958033 )
2018
27
Successful Wean Despite Emergence of Ictal-Interictal EEG Patterns During the Weaning of Prolonged Burst-Suppression Therapy for Super-Refractory Status Epilepticus. ( 29948999 )
2018
28
Perioperative management of massive fat embolism syndrome presenting as refractory status epilepticus. ( 29963415 )
2018
29
Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. ( 29943451 )
2018
30
Avoiding errors when administering injectable phenytoin to a child in status epilepticus. ( 29412538 )
2018
31
Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. ( 29399791 )
2018
32
A 15-Year-Old Boy With Refractory Status Epilepticus. ( 29961495 )
2018
33
Can endotracheal intubation be the first step in management of nonconvulsive status epilepticus?: A case report. ( 29443785 )
2018
34
Febrile infection-related epilepsy syndrome (FIRES) with super-refractory status epilepticus revealing autoimmune encephalitis due to GABA<sub>A</sub>R antibodies. ( 29203057 )
2018
35
Posterior reversible encephalopathy syndrome with status epilepticus following surgery for lumbar stenosis and spondylolisthesis: case report. ( 29864559 )
2018
36
Progression of Convulsive and Nonconvulsive Seizures During Epileptogenesis After Pilocarpine-Induced Status Epilepticus. ( 29442558 )
2018
37
Estrogen Protects Neurotransmission Transcriptome During Status Epilepticus. ( 29973860 )
2018
38
Status Epilepticus-The Hunt for Treatable Causes. ( 29961497 )
2018
39
Disseminated cysticercosis presenting as status epilepticus, rhabdomyolysis, and acute kidney injury: An unreported complication. ( 29322996 )
2018
40
Dexmedetomidine stops benzodiazepine-refractory nerve agent-induced status epilepticus. ( 29414381 )
2018
41
Transient Focal Magnetic Resonance Imaging Abnormalities After Status Epilepticus Showed 11C-Methionine Uptake with Positron Emission Tomography in a Patient with Cerebral Cavernous Malformation. ( 29530707 )
2018
42
Diazepam for outpatient treatment of nonconvulsive status epilepticus in pediatric patients with Angelman syndrome. ( 29597185 )
2018
43
A Case of Tyrosinemia Type III with Status Epilepticus and Mental Retardation. ( 29456978 )
2018
44
Rhabdomyolysis following status epilepticus with hyperuricemia: A case report and literature review. ( 29953009 )
2018
45
Inverted-U response of lacosamide on pilocarpine-induced status epilepticus and oxidative stress in C57BL/6 mice is independent of hippocampal collapsin response mediator protein-2. ( 29935443 )
2018
46
Creutzfeldt-Jakob disease with Alzheimer pathology, presenting with status epilepticus following repeated partial seizures: a case report and literature review. ( 29699515 )
2018
47
Creutzfeldt-Jakob Disease Presenting as Expressive Aphasia and Nonconvulsive Status Epilepticus. ( 29666711 )
2018
48
When aphasia is due to aphasic status epilepticus: a diagnostic challenge. ( 29255963 )
2018
49
Status epilepticus and white matter ischemia complicating dural arteriovenous fistula. ( 29790044 )
2018
50
Seizure-Induced Increased 18F-DOPA Uptake in a Child With Diffuse Astrocytoma and Transient Brain MRI Abnormalities Related to Status Epilepticus. ( 29465492 )
2018

Variations for Status Epilepticus

ClinVar genetic disease variations for Status Epilepticus:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 GALC NM_000153.3(GALC): c.850G> A (p.Gly284Ser) single nucleotide variant Pathogenic/Likely pathogenic rs377274761 GRCh38 Chromosome 14, 87968393: 87968393
2 GALC NM_000153.3(GALC): c.850G> A (p.Gly284Ser) single nucleotide variant Pathogenic/Likely pathogenic rs377274761 GRCh37 Chromosome 14, 88434737: 88434737
3 GALC NM_000153.3(GALC): c.196G> A (p.Ala66Thr) single nucleotide variant Likely pathogenic rs1057518843 GRCh38 Chromosome 14, 87988523: 87988523
4 GALC NM_000153.3(GALC): c.196G> A (p.Ala66Thr) single nucleotide variant Likely pathogenic rs1057518843 GRCh37 Chromosome 14, 88454867: 88454867

Expression for Status Epilepticus

Search GEO for disease gene expression data for Status Epilepticus.

Pathways for Status Epilepticus

Pathways related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 FOS GRIA1 GRIA2 GRIN2B JUN SCN1A
2 12.62 BDNF CASP3 FOS JUN NTRK2
3
Show member pathways
12.56 BDNF CASP3 FOS JUN NTRK2
4
Show member pathways
12.46 BDNF FOS GRIA1 GRIA2 GRIN2B NTRK2
5
Show member pathways
12.32 CASP3 GABRA4 JUN NTRK2
6
Show member pathways
12.03 BDNF FOS JUN NTRK2
7 12.01 BDNF CASP3 JUN NTRK2
8
Show member pathways
12.01 BDNF FOS GRIA1 GRIA2 GRIN2B JUN
9 11.88 BDNF CASP3 FOS GAP43 GFAP
10 11.86 CALB1 ENO2 GAP43 GFAP GRIA1 GRIA2
11
Show member pathways
11.81 CASP3 GRIA1 GRIA2 GRIN2B
12
Show member pathways
11.8 BDNF FOS GRIA1 GRIA2 GRIN2B JUN
13
Show member pathways
11.74 GRIA1 GRIA2 GRIN2B
14 11.72 BDNF CASP3 FOS GRIA1 GRIA2 GRIN2B
15 11.66 BDNF GALC GFAP
16
Show member pathways
11.63 CASP3 FOS JUN
17 11.62 CASP3 FOS JUN
18 11.54 CASP3 FOS JUN
19 11.31 CALB1 FOS JUN
20 11.27 GABRA4 GRIA1 GRIA2 GRIN2B
21 11.2 CASP3 FOS JUN
22 10.92 BDNF FOS GFAP JUN NTRK2
23 10.76 BDNF CASP3 NTRK2
24 10.67 FOS JUN

GO Terms for Status Epilepticus

Cellular components related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.95 GABRA4 GAP43 GRIA1 GRIA2 GRIN2B LGI1
2 dendrite GO:0030425 9.83 BDNF CALB1 GRIA1 GRIA2 NTRK2
3 postsynaptic density GO:0014069 9.81 GAP43 GRIA1 GRIN2B NTRK2
4 postsynaptic membrane GO:0045211 9.8 GABRA4 GRIA1 GRIA2 GRIN2B
5 neuron projection GO:0043005 9.8 CALB1 FOS GABRA4 GRIA1 GRIN2B
6 GABA-ergic synapse GO:0098982 9.63 CALB1 GABRA4 GAP43
7 axon GO:0030424 9.63 BDNF CALB1 GAP43 NTRK2 PVALB SCN1A
8 dendritic spine GO:0043197 9.62 CALB1 GRIA1 GRIA2 NTRK2
9 postsynapse GO:0098794 9.56 CALB1 GABRA4 GRIA1 GRIA2
10 synapse GO:0045202 9.5 CALB1 GABRA4 GAP43 GRIA1 GRIA2 GRIN2B
11 transcription factor AP-1 complex GO:0035976 9.37 FOS JUN
12 neuronal cell body GO:0043025 9.17 CALB1 CASP3 ENO2 GAL GRIA1 PVALB

Biological processes related to Status Epilepticus according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.85 GABRA4 GRIA1 GRIA2 SCN1A
2 nervous system development GO:0007399 9.73 BDNF FOS GAL GAP43 LGI1 NTRK2
3 response to wounding GO:0009611 9.7 CASP3 GAP43 GFAP
4 excitatory postsynaptic potential GO:0060079 9.65 GRIA1 GRIA2 GRIN2B
5 learning or memory GO:0007611 9.61 CALB1 CASP3 GRIN2B
6 long-term synaptic potentiation GO:0060291 9.58 GFAP GRIN2B NTRK2
7 response to muscle stretch GO:0035994 9.56 FOS JUN
8 chemical synaptic transmission GO:0007268 9.55 GABRA4 GRIA1 GRIA2 GRIN2B NPY
9 central nervous system neuron development GO:0021954 9.54 NPY NTRK2
10 neuronal action potential propagation GO:0019227 9.51 NTRK2 SCN1A
11 feeding behavior GO:0007631 9.5 GAL NPY NTRK2
12 regulation of postsynaptic cytosolic calcium ion concentration GO:0099566 9.49 CALB1 GRIA1
13 positive regulation of non-membrane spanning protein tyrosine kinase activity GO:1903997 9.46 BDNF NTRK2
14 brain-derived neurotrophic factor receptor signaling pathway GO:0031547 9.37 BDNF NTRK2
15 ionotropic glutamate receptor signaling pathway GO:0035235 9.13 GRIA1 GRIA2 GRIN2B
16 neurotrophin TRK receptor signaling pathway GO:0048011 8.8 BDNF CASP3 NTRK2

Molecular functions related to Status Epilepticus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 excitatory extracellular ligand-gated ion channel activity GO:0005231 9.26 GRIA1 GRIA2
2 AMPA glutamate receptor activity GO:0004971 9.16 GRIA1 GRIA2
3 ionotropic glutamate receptor activity GO:0004970 9.13 GRIA1 GRIA2 GRIN2B
4 ion channel activity GO:0005216 9.02 GABRA4 GRIA1 GRIA2 GRIN2B SCN1A

Sources for Status Epilepticus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....